Specify a stock or a cryptocurrency in the search bar to get a summary
Atossa Genetics Inc
YAG2Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Address: 107 Spring Street, Seattle, WA, United States, 98104
Analytics
WallStreet Target Price
5.42 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures YAG2
Dividend Analytics YAG2
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History YAG2
Stock Valuation YAG2
Financials YAG2
Results | 2019 | Dynamics |